Study: Solid organ transplant patients benefit from COVID-19 treatment

New research from Cedars-Sinai’s Comprehensive Transplant Center found that a monoclonal antibody treatment reduced the risk of COVID-19 in a large group of solid organ transplant patients who were administered the drug as a preventive measure against the disease.

Leave A Comment

Your email address will not be published. Required fields are marked *